Table 4.
Individual effect of serum cholinesterase on all-cause mortality.
| Exposure | Incidence, n (%) | Non-adjusted | Adjust model I | Adjust model II | |||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | ||
| Continuous cholinesterase per 1,000 U/L | |||||||
| 703 (5.98%) | 0.73 (0.70, 0.75) | <0.0001 | 0.75 (0.72, 0.78) | <0.0001 | 0.84 (0.79, 0.89) | <0.0001 | |
| Clinical cutoffs | |||||||
| <5,000 U/L | 370 (11.86%) | Reference | Reference | Reference | |||
| (5,000, 8,000) U/L | 267 (5.17%) | 0.41 (0.34, 0.48) | <0.0001 | 0.42 (0.35, 0.50) | <0.0001 | 0.62 (0.49, 0.79) | 0.0001 |
| ≥8,000 U/L | 66 (1.90%) | 0.14 (0.11, 0.19) | <0.0001 | 0.17 (0.13, 0.23) | <0.0001 | 0.28 (0.19, 0.41) | <0.0001 |
Adjust model I: Adjusted for gender, vasoactive drugs, age and intensive care unit category.
Adjust model II: Adjusted for gender, vasoactive drugs, age, intensive care unit category, cystatin C; UA; BUN; Cr; Alb; hemoglobin; GLU; ALT; AST; GGT; absolute neutrophil; absolute lymphocyte; PLT; LAC; TG; Tcho, PT.